OBJECTIVE: To analyze serial biomarkers of the persistent inflammation, immunosuppression, and catabolism syndrome (PICS) to gain insight into the pathobiology of chronic critical illness (CCI) after surgical sepsis. BACKGROUND: Although early deaths after surgical intensive care unit sepsis have decreased and most survivors rapidly recover (RAP), one third develop the adverse clinical trajectory of CCI. However, the underlying pathobiology of its dismal long-term outcomes remains unclear. METHODS: PICS biomarkers over 14 days from 124 CCI and 225 RAP sepsis survivors were analyzed to determine associations and prediction models for (1) CCI (≥14 intensive care unit days with organ dysfunction) and (2) dismal 1-year outcomes (Zubrod 4/5 performance scores). Clinical prediction models were created using PIRO variables (predisposition, insult, response, and organ dysfunction). Biomarkers were then added to determine if they strengthened predictions. RESULTS: CCI (vs RAP) and Zubrod 4/5 (vs Zubrod 0-3) cohorts had greater elevations in biomarkers of inflammation (interleukin [IL]-6, IL-8, interferon gamma-induced protein [IP-10], monocyte chemoattractant protein 1), immunosuppression (IL-10, soluble programmed death ligand-1), stress metabolism (C-reactive protein, glucagon-like peptide 1), and angiogenesis (angiopoietin-2, vascular endothelial growth factor, vascular endothelial growth factor receptor-1, stromal cell-derived factor) at most time-points. Clinical models predicted CCI on day 4 (area under the receiver operating characteristics curve [AUC] = 0.89) and 1 year Zubrod 4/5 on day 7 (AUC = 0.80). IL-10 and IP-10 on day 4 minimally improved prediction of CCI (AUC = 0.90). However, IL-10, IL-6, IL-8, monocyte chemoattractant protein 1, IP-10, angiopoietin-2, glucagon-like peptide 1, soluble programmed death ligand-1, and stromal cell-derived factor on day 7 considerably improved the prediction of Zubrod 4/5 status (AUC = 0.88). CONCLUSIONS: Persistent elevations of PICS biomarkers in the CCI and Zubrod 4/5 cohorts and their improved prediction of Zubrod 4/5 validate that PICS plays a role in CCI pathobiology.
OBJECTIVE: To analyze serial biomarkers of the persistent inflammation, immunosuppression, and catabolism syndrome (PICS) to gain insight into the pathobiology of chronic critical illness (CCI) after surgical sepsis. BACKGROUND: Although early deaths after surgical intensive care unit sepsis have decreased and most survivors rapidly recover (RAP), one third develop the adverse clinical trajectory of CCI. However, the underlying pathobiology of its dismal long-term outcomes remains unclear. METHODS: PICS biomarkers over 14 days from 124 CCI and 225 RAP sepsis survivors were analyzed to determine associations and prediction models for (1) CCI (≥14 intensive care unit days with organ dysfunction) and (2) dismal 1-year outcomes (Zubrod 4/5 performance scores). Clinical prediction models were created using PIRO variables (predisposition, insult, response, and organ dysfunction). Biomarkers were then added to determine if they strengthened predictions. RESULTS: CCI (vs RAP) and Zubrod 4/5 (vs Zubrod 0-3) cohorts had greater elevations in biomarkers of inflammation (interleukin [IL]-6, IL-8, interferon gamma-induced protein [IP-10], monocyte chemoattractant protein 1), immunosuppression (IL-10, soluble programmed death ligand-1), stress metabolism (C-reactive protein, glucagon-like peptide 1), and angiogenesis (angiopoietin-2, vascular endothelial growth factor, vascular endothelial growth factor receptor-1, stromal cell-derived factor) at most time-points. Clinical models predicted CCI on day 4 (area under the receiver operating characteristics curve [AUC] = 0.89) and 1 year Zubrod 4/5 on day 7 (AUC = 0.80). IL-10 and IP-10 on day 4 minimally improved prediction of CCI (AUC = 0.90). However, IL-10, IL-6, IL-8, monocyte chemoattractant protein 1, IP-10, angiopoietin-2, glucagon-like peptide 1, soluble programmed death ligand-1, and stromal cell-derived factor on day 7 considerably improved the prediction of Zubrod 4/5 status (AUC = 0.88). CONCLUSIONS: Persistent elevations of PICS biomarkers in the CCI and Zubrod 4/5 cohorts and their improved prediction of Zubrod 4/5 validate that PICS plays a role in CCI pathobiology.
Authors: Richard S Hotchkiss; Elizabeth Colston; Sachin Yende; Derek C Angus; Lyle L Moldawer; Elliott D Crouser; Greg S Martin; Craig M Coopersmith; Scott Brakenridge; Florian B Mayr; Pauline K Park; June Ye; Ian M Catlett; Ihab G Girgis; Dennis M Grasela Journal: Crit Care Med Date: 2019-05 Impact factor: 7.598
Authors: Laura J Moore; Bruce A McKinley; Krista L Turner; S Rob Todd; Joseph F Sucher; Alicia Valdivia; R Matthew Sailors; Lillian S Kao; Frederick A Moore Journal: J Trauma Date: 2011-03
Authors: Chanu Rhee; Raymund Dantes; Lauren Epstein; David J Murphy; Christopher W Seymour; Theodore J Iwashyna; Sameer S Kadri; Derek C Angus; Robert L Danner; Anthony E Fiore; John A Jernigan; Greg S Martin; Edward Septimus; David K Warren; Anita Karcz; Christina Chan; John T Menchaca; Rui Wang; Susan Gruber; Michael Klompas Journal: JAMA Date: 2017-10-03 Impact factor: 56.272
Authors: Julie A Stortz; Tyler J Murphy; Steven L Raymond; Juan C Mira; Ricardo Ungaro; Marvin L Dirain; Dina C Nacionales; Tyler J Loftus; Zhongkai Wang; Tezcan Ozrazgat-Baslanti; Gabriela L Ghita; Babette A Brumback; Alicia M Mohr; Azra Bihorac; Philip A Efron; Lyle L Moldawer; Frederick A Moore; Scott C Brakenridge Journal: Shock Date: 2018-03 Impact factor: 3.454
Authors: A G Cuenca; R V Maier; J Cuschieri; E E Moore; L L Moldawer; R G Tompkins Journal: Eur J Trauma Emerg Surg Date: 2011-09-02 Impact factor: 3.693
Authors: Eric Rivas; Kevin Sanchez; Janos Cambiaso-Daniel; Ileana L Gutierrez; Joan Tran; David N Herndon; Oscar E Suman Journal: J Burn Care Res Date: 2018-08-17 Impact factor: 1.845
Authors: Hiroyuki Horiguchi; Tyler J Loftus; Russell B Hawkins; Steven L Raymond; Julie A Stortz; McKenzie K Hollen; Brett P Weiss; Elizabeth S Miller; Azra Bihorac; Shawn D Larson; Alicia M Mohr; Scott C Brakenridge; Hironori Tsujimoto; Hideki Ueno; Frederick A Moore; Lyle L Moldawer; Philip A Efron Journal: Front Immunol Date: 2018-04-04 Impact factor: 7.561
Authors: Julie A Stortz; Michael C Cox; Russell B Hawkins; Gabriela L Ghita; Babette A Brumback; Alicia M Mohr; Lyle L Moldawer; Philip A Efron; Scott C Brakenridge; Frederick A Moore Journal: Crit Care Date: 2020-05-07 Impact factor: 9.097